Recently, the ANSWER trial [52] showed for the first time that long-term albumin administration, on top of a standard diuretic therapy, could be a novel therapeutic approach for patients with cirrhosis and grade 2–3 uncomplicated ascites. Here, ALB is linked to Ascites.